Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Blood

Volumn 124, Issue 8, 2014, Pages 1259-1265

  Barr, Paul M ^a   Miller, Thomas P ^b   Friedberg, Jonathan W ^a   Peterson, Derick R ^a   Baran, Andrea M ^a   Herr, Megan ^a   Spier, Catherine M ^c   Cui, Haiyan ^b   Roe, Denise J ^b   Persky, Daniel O ^b   Casulo, Carla ^a   Littleton, Jamie ^a   Schwartz, Mark ^d   Puvvada, Soham ^b   Landowski, Terry H ^b   Rimsza, Lisa M ^c   Dorr, Robert T ^b   Fisher, Richard I ^e   Bernstein, Steven H ^a   Briehl, Margaret M ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d HTG Molecular Diagnostics Inc ^*  (United States)

^e TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHLORDANE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 3; GLUTATHIONE TRANSFERASE A1; IMEXON; MANGANESE SUPEROXIDE DISMUTASE; PEROXIREDOXIN 3; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; PREDNISONE; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APPLICATION SITE PARESTHESIA; ARTICLE; B LYMPHOCYTE; BACKACHE; BURKITT LYMPHOMA; BURNING MOUTH SYNDROME; CANCER FATIGUE; CANCER PROGNOSIS; CANCER RECURRENCE; CHEMOTHERAPY INDUCED ANEMIA; CHILL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HEADACHE; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOTENSION; INSOMNIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOMA; LYMPHOMA; MALAISE; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEPSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TRANSFORMED CELL; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE PEROXIDASE; HEXANONES; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OXIDANTS; OXIDATIVE STRESS; RECURRENCE; SUPEROXIDE DISMUTASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84907362817     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-570044     Document Type: Article

References (36)

1. Weinberg F, Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci. 2009;66(23):3663-3673.
2. Sies H, Jones DP. Oxidative stress. In: Fink G, ed. Encyclopedia of Stress. Waltham, MA: Academic Press; 2007:45-48.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
4. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837.
5. Cabello CM, Bair WB III, Wondrak GT. Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs. 2007;8(12):1022-1037. (Pubitemid 350224328)
6. Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs. 2011;71(11):1385-1396.
7. Tew KD, Townsend DM. Redox platforms in cancer drug discovery and development. Curr Opin Chem Biol. 2011;15(1):156-161.
8. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridinecontaining agent imexon. Biochem Pharmacol. 2000;60(6):749-758. (Pubitemid 30621659)
9. Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT. Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anticancer Drugs. 2002;13(10): 1031-1042. (Pubitemid 36020673)
10. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT. Induction of mitochondrial changes in myeloma cells by imexon. Blood. 2001;97(11):3544-3551.
11. Pourpak A, Meyers RO, Samulitis BK, et al. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anticancer Drugs. 2006;17(10):1179-1184. (Pubitemid 44673398)
12. Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Mol Cancer Res. 2012;10(3):392-400.
13. Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst. 1992; 84(16):1238-1244.
14. Hersh EM, Grogan TM, Funk CY, Taylor CW. Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy. J Immunother Emphasis Tumor Immunol. 1993;13(2):77-83. (Pubitemid 23047407)
15. Moulder S, Dhillon N, Ng C, et al. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs. 2010;28(5):634-640.
16. Dragovich T, Gordon M, Mendelson D, et al. Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol. 2007;25(13):1779-1784. (Pubitemid 46797961)
17. Tome ME, Johnson DB, Rimsza LM, et al. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood. 2005;106(10):3594-3601. (Pubitemid 41609198)
18. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
19. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
20. Roberts LJ II, Moore KP, Zackert WE, Oates JA, Morrow JD. Identification of the major urinary metabolite of the F2-isoprostane 8-isoprostaglandin F2alpha in humans. J Biol Chem. 1996;271(34):20617-20620. (Pubitemid 26281840)
21. Roberts RA, Sabalos CM, LeBlanc ML, et al. Quantitative nuclease protection assay in paraffinembedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Invest. 2007;87(10):979-997. (Pubitemid 47429191)
22. Bhalla S, Gordon LI, David K, et al. Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. Br J Haematol. 2010;150(3):365-369.
23. Chang JE, Voorhees PM, Kolesar JM, et al. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol. 2009;27(1):11-16.
24. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol. 2008;141(4):494-503. (Pubitemid 351550556)
25. Dvorakova K, Payne CM, Tome ME, et al. Molecular and cellular characterization of imexonresistant RPMI8226/I myeloma cells. Mol Cancer Ther. 2002;1(3):185-195.
26. Moehler TM, Feneberg R, Ho AD, et al. Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. Anticancer Drugs. 2010;21(7):708-715.
27. Cohen SJ, Zalupski MM, Modiano MR, et al. A phase I study of imexon plus gemcitabine as firstline therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol. 2010;66(2):287-294.
28. Weber JS, Samlowski WE, Gonzalez R, et al. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010;116(15):3683-3691.
29. MacGregor JT. Biomarkers of cancer risk and therapeutic benefit: new technologies, new opportunities, and some challenges. Toxicol Pathol. 2004;32(Suppl 1):99-105. (Pubitemid 38437573)
30. Rolan P, Atkinson AJ Jr, Lesko LJ; Scientific Organizing Committee; Conference Report Committee. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther. 2003;73(4):284-291. (Pubitemid 36403588)
31. Powis G, Briehl M, Oblong J. Redox signalling and the control of cell growth and death. Pharmacol Ther. 1995;68(1):149-173.
32. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511. (Pubitemid 30082188)
33. Peroja P, Pasanen AK, Haapasaari KM, et al. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Exp Hematol Oncol. 2012; 1(1):2.
34. Gouazé V, Mirault ME, Carpentier S, Salvayre R, Levade T, Andrieu-Abadie N. Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol. 2001;60(3):488-496. (Pubitemid 32781555)
35. Jaramillo MC, Frye JB, Crapo JD, Briehl MM, Tome ME. Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells. Cancer Res. 2009;69(13):5450-5457.
36. Nathan CF, Arrick BA, Murray HW, DeSantis NM, Cohn ZA. Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med. 1981;153(4):766-782. (Pubitemid 11104727)